Libtayo® (cemiplimab) demonstrates durable survival benefit at five years in advanced non-small cell lung cancer

Late-breaking data at wclc show libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy
REGN Ratings Summary
REGN Quant Ranking